Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA...
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
GAITHERSBURG, Md. , Dec. 16, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety,...
Emergent BioSolutions Reports Financial Results For Third Quarter 2021
GAITHERSBURG, Md. , Nov. 04, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2021 ....
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
GAITHERSBURG, Md. , Oct. 18, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
GAITHERSBURG, Md. , Oct. 15, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and...
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Total baseline value for Emergent is approximately $90 million USD , further expanding the collaboration between the companies, which began in February 2021 GAITHERSBURG, Md. and CALGARY, Alberta ,...
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential...
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md. , July 29, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the...
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
GAITHERSBURG, Md. , July 29, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview...
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
Emergent BioSolutions joins forces with an alliance of advocacy organizations that share a common goal to empower open communication and address the stigma of opioid overdoses, which are oftentimes...
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
GAITHERSBURG, Md. , July 15, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the...
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production GAITHERSBURG, Md. , June 11, 2021 (GLOBE...